Core Viewpoint - Anteris Technologies Global Corp. has announced a public offering of 34,782,609 shares at a price of $5.75 per share, aiming to raise approximately $200 million before expenses [1][2]. Group 1: Offering Details - The public offering consists entirely of shares sold by the Company, with underwriters granted a 30-day option to purchase an additional 5,217,391 shares [2]. - The Offering is expected to close on January 22, 2026, pending customary closing conditions [1]. - The shares are being offered under a shelf registration statement filed with the SEC, which was declared effective on January 8, 2026 [6]. Group 2: Private Placement - Anteris has agreed to sell up to $90 million of shares to Medtronic plc in a private placement, contingent on the completion of the public offering [3]. - The private placement will require a minimum purchase of 16% and a maximum of 19.99% of the shares outstanding after the public offering [3]. Group 3: Use of Proceeds - The net proceeds from the Offering and the Private Placement will support the growth and clinical strategy of the Company, including the DurAVR Transcatheter Heart Valve global pivotal trial [4]. - Funds will also be allocated to expand manufacturing capabilities and ongoing research and development for v2vmedtech, inc., with remaining proceeds for working capital and general corporate purposes [4]. Group 4: Company Overview - Anteris Technologies is focused on developing innovative medical devices for heart function restoration, with a significant presence in both Australia and the USA [10]. - The lead product, DurAVR THV, is designed to treat aortic stenosis and is the first biomimetic valve, utilizing patented ADAPT tissue technology [11].

Core Viewpoint - Anteris Technologies Global Corp. has announced a public offering of 34,782,609 shares at a price of $5.75 per share, aiming to raise approximately $200 million to support its growth and clinical strategy [1][4]. Group 1: Offering Details - The public offering consists of 34,782,609 shares priced at $5.75 each, with expected gross proceeds of around $200 million before expenses [1]. - The underwriters have a 30-day option to purchase an additional 5,217,391 shares at the public offering price [2]. - The offering is set to close on January 22, 2026, pending customary closing conditions [1]. Group 2: Private Placement - Anteris has agreed to sell up to $90 million of shares to Medtronic plc in a private placement, with a minimum purchase of 16% and a maximum of 19.99% of the shares outstanding after the offering [3]. - The completion of the private placement is contingent on the successful completion of the public offering [3]. Group 3: Use of Proceeds - The net proceeds from the offering and private placement will be used to advance the clinical strategy, including the DurAVR® THV global pivotal trial for severe aortic stenosis [4]. - Additional funds will support the expansion of manufacturing capabilities and ongoing research and development for v2vmedtech, inc., with remaining funds allocated to working capital and general corporate purposes [4]. Group 4: Company Overview - Anteris Technologies is a global structural heart company focused on developing innovative medical devices to restore heart function [10]. - The lead product, DurAVR® THV, is designed to treat aortic stenosis and is made from Anteris' patented ADAPT® tissue technology, which has been used in over 55,000 patients worldwide [11].

January 20, 2026 05:15 PM GMT China Healthcare | Asia Pacific Medical Devices – 2025 Results Preview and Initial 2026 Outlook For 2026, IVD players will face ongoing pricing pressures, mitigated in part by import substitution. Medical equipment sales may see a modest recovery. Meanwhile, niche consumable segments could see additional gains on VBP and globalization tailwinds. Key OWs: Zylox & APT Medical; UW: Imeik. Key Takeaways Downgrade Imeik (300896.SZ) to UW from EW; PT unchanged at Rmb130: Intensifying ...

1月21日，A股震荡回升，创业板涨超1%，黄金股继续走强，存储芯片、GPU概念拉升，AI应用板块继续调整。港 股早盘一度下跌，随后震荡走高，科网股分化，半导体、化工等板块上涨。债市方面，国债期货多数下跌。商品方 面，国内商品期货涨跌不一，碳酸锂继续大涨超5%，前一个交易日涨停，焦煤跌超3%。核心市场走势： | 代码 | 名称 | 两日图 | 现价 | | 涨跌幅 | | --- | --- | --- | --- | --- | --- | | 000001 | 上证指数 | Sam | 4123.59 | 9.94 | 0.24% | | 399001 | 深证成指 | MA | 14242.47 | 86.84 | 0.61% | | 399006 | 创业板指 | Mar | 3313.01 | 35.03 | 1.07% | | 000300 | 沪深300 | bor | 4739.19 | 20.31 | 0.43% | | 000016 | FiFFSO | Smi | 3084.81 | 14.16 | 0.46% | | 000680 | 科创综 | m | 1857.11 | 36.63 ...

LITTLETON, Colo., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (Nasdaq: VVOS), a leading medical device and healthcare services company focused on sleep related breathing disorders, including obstructive sleep apnea (OSA), today announced the closing of its previously announced exercise of certain outstanding warrants to purchase up to an aggregate of 1,982,356 shares originally issued in January 2023, November 2023 and February 20, 2024, at exercise prices rangin ...

Core Viewpoint - Anteris Technologies Global Corp. is initiating a public offering of $200 million in common stock, with an additional $30 million option for underwriters, alongside a private placement of up to $90 million to Medtronic plc, aimed at supporting growth and clinical strategy execution [1][2][3]. Group 1: Offering Details - The company is offering $200 million of its common stock through a proposed underwritten public offering, with a 30-day option for underwriters to purchase an additional $30 million [1]. - Anteris has agreed to sell up to $90 million of common stock to Medtronic in a private placement, contingent on the completion of the public offering [2]. - The shares in the public offering are being offered under a shelf registration statement filed with the SEC, effective January 8, 2026 [5]. Group 2: Use of Proceeds - The net proceeds from the offering and private placement will be used to support the next stage of growth, including the PARADIGM Trial for the DurAVR Transcatheter Heart Valve and expansion of manufacturing capabilities [3]. - A portion of the proceeds will also fund ongoing research and development for v2vmedtech, inc., with the remainder allocated to working capital and general corporate purposes [3]. Group 3: Company Overview - Anteris Technologies is a global structural heart company focused on developing medical devices to restore heart function, with a significant presence in both Australia and the USA [9]. - The company's lead product, the DurAVR THV, is designed to treat aortic stenosis and is the first biomimetic valve, utilizing patented ADAPT tissue technology [10].

Key Takeaways ISRG's Q4 prelims showed 18% procedure growth, roughly $2.87B revenues and 532 da Vinci system placements.ISRG's I&A revenues rose 17% on higher procedures, though pricing pressure remained in China and ASC settings.ISRG saw strong da Vinci 5 demand lift system ASPs, while tariffs and margins weighed on earnings outlook.Intuitive Surgical, Inc. (ISRG) is set to report fourth-quarter 2025 earnings on Feb. 22. The Zacks Consensus Estimate for sales and earnings is pegged at $2.87 billion and $2. ...

Intuitive Surgical, Inc. (NASDAQ:ISRG) is one of the stocks on Jim Cramer’s game plan for this week. Cramer was bullish on the company’s upcoming quarter, as he said: "What else? I think that the lone surprise blowout next week will come from Intuitive Surgical, which had a monster quarter last time. But I bet that the numbers still aren’t high enough. That means that the estimates can go higher. One day, these upside surprises will come to an end, I think, because competition from Medtronic may matter. E ...

J&J announced plans to separate its Orthopaedics business into a standalone company called DePuy Synthes. The move will be completed within 18 to 24 months."Our surgical technologies are used in most operating rooms globally. And in Q3, we delivered more than 9% growth in biosurgery and almost 7% in wound closure, driven by accelerating adoption of our latest innovations," Schmid said.Tim Schmid, Executive Vice President of MedTech at J&J, emphasized the company's commitment during the recent earnings call ...

We came across a bullish thesis on Enovis Corporation on Value investing subreddit by TheBestOfAllTylers. In this article, we will summarize the bulls’ thesis on ENOV. Enovis Corporation's share was trading at $24.66 as of January 13th. ENOV’s forward P/E was 6.85 according to Yahoo Finance. wavebreakmedia/Shutterstock.com Enovis operates as a specialized challenger platform in musculoskeletal healthcare, combining a high-margin, surgeon-driven implant franchise with a faster-turning but lower-margin pr ...